Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has acquired key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery.   Ginkgo has acquired Reverie’s infrastructure and software for training large-scale AI foundation models and four of Reverie’s key AI team members. The acquisition is intended to strengthen Ginkgo’s AI/ML-driven discovery services offering and to accelerate Ginkgo’s work to build next...